• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nanoparticles

Researchers use microparticles for targeted delivery of brain cancer therapy

August 7, 2018 By Sarah Faulkner

MIT - Glioma therapy

A team of researchers from Brigham & Women’s Hospital, Mass. Institute of Technology and Mass. General Hospital demonstrated that localizing the delivery of NAMPT inhibitors can extend survival in a mouse model of glioma, according to a paper published this week in the Proceedings of the National Academy of Sciences. The scientists created a test to […]

Filed Under: Drug-Device Combinations, Featured, Nanoparticles, Oncology, Pharmaceuticals, Research & Development Tagged With: Brigham & Women's Hospital, Massachusetts General Hospital, Massachusetts Institute of Technology

Nanobiotix inks $47m financing to support nanomedicine development

July 30, 2018 By Sarah Faulkner

Nanobiotix nanoparticle

Nanobiotix (PAR:NANO.PA) inked a non-dilutive financial deal with the European Investment Bank last week to support the development of its nanoparticle-based cancer therapies. The Paris, France-based company said it landed a five-year loan to borrow up to €40 million ($46.7 million) contingent upon a set of performance milestones. Nanobiotix plans to use the funds to bring its NBTXR3 […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Nanoparticles, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: nanobiotix

Takeda, leon-nanodrugs ink feasibility testing deal for reformulated drug

July 17, 2018 By Sarah Faulkner

Takeda, Leon Nanodrugs

leon-nanodrugs said today that Takeda (TYO:4502) tapped its MicroJet Reactor technology as part of a feasibility study that could result in the reformulation of one of Takeda’s pipeline products. Using leon’s nanotechnology platform, the companies plan to boost the solubility, bioavailability and stability of one of Takeda’s pipeline products. Positive results from the feasibility study could […]

Filed Under: Featured, Nanoparticles, Pharmaceuticals, Wall Street Beat Tagged With: leon-nanodrugs GmbH, Takeda Pharmaceutical Co

Ocugen launches Ph3 trial for eye disease nanoemulsion

July 2, 2018 By Sarah Faulkner

Ocugen logo

Ocugen said today that it launched the first of two pivotal Phase III trials for its OCU300 nanoemulsion designed to treat the symptoms of ocular graft versus host disease. The Malvern, Penn.-based company’s drug is a nanoemulsion formulation of brimonidine tartrate made using Ocugen’s OcuNanoE technology. Ocugen touted that it’s the first company to bring […]

Filed Under: Clinical Trials, Featured, Nanoparticles, Optical/Ophthalmic, Pharmaceuticals Tagged With: ocugen

Precision NanoSystems raises $6m to fund nanomedicine manufacturing tech

June 8, 2018 By Sarah Faulkner

Precision NanoSystems

Vancouver-based Precision NanoSystems said today that it closed a $6m Series B round, with investments from 5AM Ventures, Telegraph Hill Partners and Rising Tide Fund. The company is slated to use its newly-acquired funds to support the expansion of its services, including its nanomedicine manufacturing platform, NanoAssemblr. Precision NanoSystems’ technology is designed to enable the […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Nanoparticles, Pharmaceuticals Tagged With: precisionnanosystems

MIT researchers devise single-injection delivery method for polio vaccine

May 22, 2018 By Sarah Faulkner

MIT polio vaccine

Although most of the world is protected from the polio virus thanks to a vaccine developed decades ago, some countries remain vulnerable to the disease thanks to challenges posed by a vaccine that requires repeat dosing. Researchers from the Massachusetts Institute of Technology want to change that with a nanoparticle vaccine that can deliver multiple […]

Filed Under: Drug-Device Combinations, Featured, Nanoparticles, Pharmaceuticals, Research & Development Tagged With: Massachusetts Institute of Technology

Will medtech drive the next Southeastern U.S. industrial revolution?

April 30, 2018 By Chris Newmarker

South Carolina Southeastern U.S. medtech

Paul Snyder, Write2Market Once home to a thriving textile industry replete with chemical and mechanical engineers working to improve the soil and machinery converting raw cotton into commercial goods, upstate South Carolina may be on the precipice of its next industrial revolution: medtech. Born from technology developed at the Albert Einstein College of Medicine, Greenville-based […]

Filed Under: Business/Financial News, Featured, Nanoparticles Tagged With: alberteinsteincollegeofmedicine, clemsonuniversity, cubeinc, southcarolina, southeasternmedicaldeviceassociation, startups, write2market, zylotherapeutics

NanOlogy looks to transform chemotherapy with localized delivery platform

March 5, 2018 By Sarah Faulkner

NanOlogy

Paclitaxel revolutionized cancer treatment when it was first used as a chemotherapeutic in the 1990s. But although the product is a powerful cancer killer, patients taking systemic doses of paclitaxel have to endure side effects such as peripheral neuropathy and hair loss. Marc Iacobucci and his team at NanOlogy believe they could replace the need […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Nanoparticles, Oncology, Pharmaceuticals, Regulatory/Compliance, Research & Development, Wall Street Beat Tagged With: nanology

Nanobiotix’s nanoparticle-immunotherapy trial wins FDA approval

December 26, 2017 By Sarah Faulkner

Nanobiotix nanoparticle

Nanobiotix (EMA:NANO) said today that the FDA has approved its IND application for a cancer trial combining its radiotherapy-activated nanoparticle tech with an anti-PD1 antibody. The Phase I/II trial is slated to evaluate the safety and efficacy of Nanobiotix’s NBTXR3 product administered with checkpoint inhibitors in three groups of patients with recurrent or metastatic head and […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Nanoparticles, Oncology, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: nanobiotix

Aura Biosciences raises $30m for nanoparticle cancer treatment

December 21, 2017 By Sarah Faulkner

Aura Biosciences

Aura Biosciences has closed a $30 million Series C round with funding from new investors like Arix Bioscience and Lundbeckfonden Ventures, as well as existing investors, including the estate of former-Genzyme CEO Henri Termeer, who died earlier this year. The privately-held biotech is developing a light-activated nanoparticle therapy for patients with ocular melanoma. Aura said […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Nanoparticles, Oncology, Optical/Ophthalmic, Pharmaceuticals, Research & Development Tagged With: Aura Biosciences

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 10
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS